WilliamHill¹Ù·½ÍøÕ¾

OAÈë¿Ú
±¨¸æµ¥ÅÌÎÊ
ÔÚÏ߿ͷþ
ÍþÁ®Ï£¶û¡¤williamhill(Öйú)ÖÐÎĹٷ½ÍøÕ¾
ÐÂÎÅÖÐÐÄ
News Center
AIÊÖÒÕÖØ¹¹ÑªÒºÖ×ÁöÒ½ÁÆ·¶Ê½£ºWilliamHill¹Ù·½ÍøÕ¾ÏîÄ¿ÈëÑ¡2025Äê¶Èº¼ÖÝÊÐÖØµã¿ÆÑÐÍýÏë
Ðû²¼£º2025/07/23

¿ËÈÕ £¬º¼ÖÝÊпÆÑ§ÊÖÒÕ¾ÖÐû²¼¡¶2025Äê¶Èº¼ÖÝÊÐÖØµã¿ÆÑÐÍýÏëÏîÄ¿£¨µÚÒ»Åú£©ÄâÁ¢ÏîÏîÄ¿Çåµ¥¡· £¬²¢ÒÑÍê³É¹«Ê¾¡£WilliamHill¹Ù·½ÍøÕ¾ÆìϺ¼ÖÝWilliamHill¹Ù·½ÍøÕ¾Ò½Ñ§Ä¥Á·ÖÐÐÄÓÐÏÞ¹«Ë¾É걨µÄ¡°ÁÙ´²×¨²¡¸¨Öú¾öÒéϵͳÑз¢¼°Ó¦Ó᪡ªÑªÒºÖ×Áö¶àģ̬ÖÇÄܸ¨Öú¾öÒéϵͳÑз¢¼°Ó¦Óá±ÏîÄ¿ÀÖ³ÉÈëÑ¡ £¬±ê¼Ç׏«Ë¾ÔÚѪҺÖ×Áö¾«×¼ÕïÁÆÁìÓòµÄÊýÖÇ»¯Êµ¼ùÔÙ»ñȨÍþÈϿɡ£

11.png

º¼ÖÝÊпÆÑ§ÊÖÒÕ¾Ö¹«Ê¾Ò³Ãæ½ØÍ¼


ÁÙ´²Ö®Í´£ºÑªÒºÖ×ÁöÕïÁÆÖØ´óÐÔ¸ß


ѪҺÖ×ÁöµÄÕïÁÆÍ¨³£Éæ¼°¶àÖÖÖØ´óµÄÕï¶ÏÊÖÒÕ £¬¼´MICM×ÛºÏÕï¶Ï £¬Æä°üÀ¨ÐÎ̬ѧ¼°Ï¸°û»¯Ñ§£¨Morphology £¬M£©¡¢ÃâÒßѧ£¨Iummunity £¬I £¬Á÷ʽϸ°ûÃâÒ߯ÊÎöºÍ/»ò²¡ÀíÃâÒß×éÖ¯»¯Ñ§£©¡¢È¾É«ÌåºËÐÍÆÊÎö£¨Cytogenetics £¬C£©¡¢·Ö×ÓÉúÎïѧÊÖÒÕ£¨Molecular £¬M£©¡£Í¨¹ý×ÛºÏÒÔÉÏÒªÁìµÄ¸÷×ÔÓÅÊÆ £¬Äܹ»Ô½·¢ÖÜÈ«¡¢×¼È·µØ¶ÔѪҺÖ×Áö¾ÙÐÐÕï¶Ï¡¢·ÖÐÍ¡¢Ô¤ºóÅжÏÒÔ¼°ÁÆÐ§¼à²â £¬´Ó¶ø¸üºÃµØÖ¸µ¼ÁÙ´²ÖÎÁÆ¡£

 

ÔÚÔçÆÚÕï¶Ï¡¢Ô¤ºóÕ¹Íû¡¢ÁÆÐ§¼à²âµÈ¶à¸ö»·½Ú £¬ÑªÒºÖ×ÁöµÄÕïÁÆ»¹±£´æ´ó×ÚÁÙ´²Í´µã¡£ºÃ±È £¬ÔÚÂýÐÔËèϵ°×Ѫ²¡£¨CML£©ÖÐ £¬²¿·ÖʹÓðÐÏòÒ©ÎïºóÈ¡µÃÓÅÒìÁÆÐ§µÄ»¼Õß £¬¿ÉÒÔʵÏÖÍ£Ò©ºóµÄÎÞÖÎÁÆ»º½â £¬¶øÏÖÐÐÁÙ´²Ö¸ÄϺÍÏà¹ØÑо¿ÖÐÅú×¢Ö»ÓÐÔ¼50%µÄ»¼ÕßÄܹ»Í£Ò©ÀÖ³É £¬ÔõÑù¸ü¾«×¼µØÕÒµ½ÊʺÏÍ£Ò©µÄ»¼Õß £¬³ÉΪ¼±Ðè½â¾öµÄÎÊÌâ¡£¼±ÐÔËèϵ°×Ѫ²¡£¨AML£©»¼ÕßÖÎÁƼƻ®µÄÖÆ¶© £¬Í¨³£ÐèÒª²Î¿¼¶àÖÖ¼ì²âÖ¸±ê £¬Õë¶Ô²î±ðΣº¦µÄ»¼ÕßΪҽÉúÌṩ¿ìËÙ¾öÒéÊý¾ÝÒÀ¾Ý £¬³ÉΪ°ü¹ÜÁÆÐ§µÄ»ù´¡¡£

 

Òò´Ë £¬ÎÞÂÛÊǽ«ÖØ´óÕï¶ÏÁ÷³Ì¾ÙÐÐ×Ô¶¯»¯Éý¼¶ÒÔÌáÉýЧÂÊ £¬ÕվɴÓÖØ´óµÄ¶àģ̬Êý¾ÝÖÐÕÒ³öÒªº¦µÄ¾öÒéµã £¬È˹¤ÖÇÄܶ¼Êǽâ¾öÏÖÓÐÁÙ´²ÎÊÌâµÄÒªº¦¡£


ÆÆ¾ÖÀûÆ÷£º AI¶àģ̬¾öÒéϵͳµÄÊÖÒÕÆÆ¾Ö


ÃæÁÙÖ×Áö°ÐÏòÖÎÁÆÍ£Ò©ºó¾Ó¸ß²»Ïµĸ´·¢Î£º¦¡¢¼±ÐÔ°×Ѫ²¡×ªË²¼´ÊŵĻƽð¾ÈÖÎʱ¼ä´°ÒÔ¼°¶à·¢ÐÔ¹ÇËèÁö£¨MM£©ÁÆÐ§ÆÀ¹À¶ÔÖØ¸´ÇÖÈëÐԹǴ©µÄ¸ß¶ÈÒÀÀµµÈؽ´ýÍ»ÆÆµÄÁÙ´²Äæ¾³ £¬WilliamHill¹Ù·½ÍøÕ¾×¤×ãÁÙ´²ÐèÇó £¬¿ªÕ¹¡°ÑªÒºÖ×Áö¶àģ̬ÖÇÄܸ¨Öú¾öÒéϵͳÑз¢¼°Ó¦Óá±ÏîÄ¿¡£


¸ÃÏîÄ¿½«ÖÂÁ¦ÓÚÉî¶ÈÕûºÏ°üÀ¨ÕæÊµÌìÏÂÓÃÒ©Êý¾Ý¡¢¶à×éѧ·Ö×Ó·ÖÐÍ¡¢¶¯Ì¬Ó°ÏñѧÐÅÏ¢¼°»¼ÕßÈ«²¡³Ì¹ÜÀí¼Í¼ÔÚÄڵĺ£Á¿¶àά¶ÈÊý¾Ý £¬²¢ÔËÓÃÇ°ÑØÈ˹¤ÖÇÄÜÊÖÒÕ£¨AI£©¾ÙÐÐÖÇÄÜÆÊÎöÓëÉî¶ÈÍÚ¾ò £¬Ö¼ÔÚ¹¹½¨Ò»Ì×Í»ÆÆÐÔµÄÁÙ´²¾öÒéÖ§³Öϵͳ £¬ÎªÕâЩÑÏËàÌôÕ½Ìṩ¾«×¼¡¢¸ßЧÇÒ·ÇÇÖÈëÐÔµÄÁ¢Òì½â¾ö¼Æ»®¡ª¡ª


1. CML¡°Í£Ò©ÖúÊÖ¡±¡ª¡ªÈÃTKIÇå¾²¼õÁ¿³ÉΪ¿ÉÄÜ

°ÐÏòÒ©£¨TKI£©ËäÓÐÓà £¬µ«ºã¾Ã·þÓÃ»á¸ø»¼Õß´øÀ´¸±×÷Óú;­¼Ã¼ç¸º¡£Ïà¹ØÑо¿ÏÔʾ £¬Ô¼50%µÖ´ïÉî¶È»º½â£¨DMR£©²¢ÊµÑéÍ£Ò©µÄ»¼Õ߻Ḵ·¢¡¾1¡¿¡£±¾ÏîÄ¿½«Í»ÆÆ½öÒÀÀµ·Ö×Ó»º½âʱ³¤µÄ¾ÖÏÞ £¬Á¢ÒìÐÔµØÕûºÏ¹ÇËèͿƬ¡¢¶à²ÎÊýÁ÷ʽ£¨¼à²âÃâÒß״̬ÈçNKϸ°û¡¢ºÄ½ßTϸ°û£©¡¢Ï¸°ûÒò×ӵȡ°ÃâÒß×éѧ¡±Êý¾Ý £¬¹¹½¨AIÕ¹ÍûÄ£×Ó £¬Îª»¼ÕßÊä³ö¸öÐÔ»¯µÄ¡°Í£Ò©/¼õÒ©ÀֳɸÅÂÊ¡±ºÍ¸´·¢Î£º¦ÆÀ¹À £¬ÈÃÇ徲ͣҩ³ÉΪ¿ÉÄÜ¡£


2. AML¡°7Ìì¼Æ»®ÍƼöÆ÷¡±¡ª¡ª½ô×¥ÖÎÁÆ»Æ½ð´°¿ÚÆÚ

AMLÏ£ÍûѸÃÍ £¬ÖÎÁÆ´°¿ÚÆÚ¶Ì¡£»ùÒò¼ì²âµÄÆÚ´ýʱ¼ä³ÉΪÕïÁÆÖÐµÄÆ¿¾±¡£±¾ÏîÄ¿½«Ñз¢¹ÇËèͿƬÃë¼¶¶àģ̬ÆÊÎöÊÖÒÕ £¬Ê¹ÓÃAIÖ±½Ó´ÓͿƬͼÏñÖÐʵʱ¶¨Î»ÈçFLT3-ITD¡¢NPM1µÈÒªº¦Çý¶¯Í»±ä £¬ÔÚ»¼Õß¾ÙÐл¯ÁÆ»ò¾ÙÐаÐÏòÓÃÒ©7ÌìÄÚÊä³öÓÐÓÃÐÔ¸ÅÂʺÍ×¥ÊÖÐÔÍ»±äÒ©ÎïÆ¥Å佨Òé¡£ºóÐøÔÙÍŽáÁ÷ʽÃâÒß·ÖÐͺͻùÒò²âÐòÊý¾Ý £¬¶¯Ì¬Ð£×¼Î£º¦·Ö²ãºÍÒ©ÎïÆ¥Åä £¬ÏÔÖøËõ¶ÌÖÎÁƿմ°ÆÚ £¬ÌáÉýÉúÑÄÂÊ¡£


3.MM¡°ÎÞ´´AI-MRD¼à²â¡±¡ª¡ªÍâÖÜÑªÌæ»»¹ÇËè´©´Ì

ÖØ¸´¹ÇËè´©´ÌÊÇMM»¼Õ߯À¹ÀÁÆÐ§ºÍ¸´·¢µÄÖ÷Ҫʹ¿àȪԴ¡£±¾ÏîÄ¿½«¹¹½¨»ùÓÚÍâÖÜѪµÄÖÇÄÜMRDÆÀ¹Àϵͳ £¬Í¨¹ýAIÈÚºÏÍâÖÜѪÁ÷ʽ£¨Ñ­»·½¬Ï¸°û£©¡¢¶¨Á¿M-ÂѰ×ÖÊÆ×¡¢ÓÎÀëÖ×ÁöDNA(ctDNA)µÈ¶àģ̬¶¯Ì¬Êý¾Ý £¬Êä³ö¿ÉÚ¹Ê͵ġ°AI-MRD¸ÅÂÊ·ÖÖµ¡± £¬ÊµÏ֏߯µ¡¢ÎÞ´´¡¢È«¾°µÄ²ÐÁôÁö¸ººÉ¼à²â¡£Õâ²»µ«ÄܼõÇỼÕßÍ´¿à £¬¸üÄÜÔçÆÚʶ±ð¸ß¸´·¢Î£º¦ £¬Ö¸µ¼Î¬³ÖÖÎÁƵ÷½â¡£



Éç»á¼ÛÖµ£º´Ó¾«×¼Ò½ÁƵ½Íƶ¯ÎÀÉú¾­¼Ãѧ¸ïÃü


ѪҺÖ×Áöºã¾Ãλ¾Ó¶ñÐÔÖ×ÁöÖÂËÀÂÊǰÏß £¬Æä¶ñ»¯¿ì¡¢Ò׸´·¢¡¢ÕïÁÆÓöȸß¡£ÒÆÖ²¡¢°ÐÏòÒ©¡¢CAR-TËä°ÑÉúÑÄÏ£ÍûÍùÇ°ÍÆÁËÒ»´ó²½ £¬µ«¶¯éü¼¸Ê®ÍòÒÔÖÂÉϰÙÍòµÄÆÆ·Ñ £¬ÈÃÎÞÊý¼ÒÍ¥¡°¿´µÃ¼ûÏ£Íû £¬¹»²»×ÅÒ©¡±¡£


±¾ÏîÄ¿Ñз¢µÄ¶àģ̬AIѪҺÖ×Áö¾öÒéϵͳ £¬¾ÍÊÇΪÁËÍÆ¶¯¼â¶ËÖÎÁÆÆ½¼Û¿É¼°¡£Ëü½«°ÑÔ­±¾ÐèÒªÊýСʱµÄÖØ´ó¼ì²âѹËõµ½¡°Ãë¼¶¡± £¬ÈÃÂÄÀúÓÃÒ©Éý¼¶Îª¡°Ç§ÈËǧ·½¡±¡£»ùÓÚÿλ»¼ÕßÁ¿Éí¶¨ÖÆµÄÔ¤·À¡¢Õï¶Ï¡¢ÖÎÁÆÒ»Ì廯¼Æ»® £¬¼È¾«×¼ÓÖʡǮ £¬ÖÜÈ«Â䵨ºóÔ¤¼Æ¿ÉΪº£ÄÚÒ½±£ºÍ»¼Õß¼ÒÍ¥½ÚÔ¼ÉÏÒÚÔªÖ§³ö £¬Èþ«×¼Ò½ÁÆÕæÕý×ß½øÑ°³£ÀèÃñ¼Ò¡£


µ±ÑªÒºÖ×ÁöÓö¼û¶àģ̬AI £¬ÎÒÃÇÕý¼ûÖ¤Ò»³¡ÕïÁÆ·¶Ê½µÄÖØ¹¹£º¸üÔçµÄ¸ÉÔ¤¡¢¸ü×¼µÄ¾öÒé¡¢¸üÇáµÄÍ´¿à¡£ÏîÄ¿Ñз¢Àú³ÌÖÐ £¬WilliamHill¹Ù·½ÍøÕ¾»¹½«ÍŽáÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½Ôº¡¢»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥ÊôЭºÍÒ½Ôº¡¢ÎÂÖÝÒ½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½ÔºµÈ¶à¼ÒÍ·²¿Èý¼×Ò½Ôº £¬¿ªÕ¹Ç°Õ°ÐÔ±ÈÕÕÑо¿ £¬È·±£Ëã·¨¿ÉÚ¹ÊÍ¡¢¿ÉÂ䵨¡£



½ô¸ú¡°¿µ½¡Öйú¡±¡°Êý×ÖÖйú¡±¹ú¼ÒÕ½ÂÔ°²ÅÅ £¬WilliamHill¹Ù·½ÍøÕ¾½«Ãª¶¨¡°Ò½Ñ§Õï¶ÏÖÇÄܽâ¾ö¼Æ»®ÒýÁìÕß¡±µÄÕ½ÂÔ¶¨Î» £¬Ò»Á¬Éî¸ûÒ½ÁÆ¿µ½¡³¡¾° £¬ÒÔ¡°AI+Êý¾Ý¡±ÎªÒýÇæ £¬ÒÔ½¹µã×ÔÑÐÊÖÒÕΪÇý¶¯Á¦ £¬Ò»Ö±ÌáÉýÕïÁƾ«×¼¶È¡¢Á¢Ò쿵½¡¹ÜÀíģʽ £¬ÒýÁ칤ҵÉú̬ÖÇÄÜ»¯Î´À´¡£


²Î¿¼ÎÄÏ×£º

1. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757.


ÍøÕ¾µØÍ¼